Points - Recent Research
Effect of Ultrasound-Guided Acupotomy vs Electro-Acupuncture on Knee Osteoarthritis
Epigallocatechin Gallate Upregulates NRF2 to Prevent Diabetic Nephropathy via Disabling KEAP1
Effects of Astragalus Combined with Angelica on Bone Marrow Hematopoiesis Suppression Induced by Cyclophosphamide in Mice

Effect of Ultrasound-Guided Acupotomy vs Electro-Acupuncture on Knee Osteoarthritis

Ding Y, et al.

OBJECTIVE: To investigate the effect of acupotomy on knee osteoarthritis (KOA), compared to electro- acupuncture (EA).
METHODS: Sixty KOA patients were randomly divided into 2 groups: ultrasound-guided acupotomy group and EA group; each had 3 weeks' therapy. After the treatment, by contrast before and after therapy, by comparing curative effects among groups, we looked into disease improvement degree through activities of daily living score (ADL), hospital for special surgery index (HSS), visual analogue scales score (VAS) and knee joint's infrared thermal imaging detection.
RESULTS: Graded by ADL, the excellent rate in acupotomy group was much higher than EA group; both acupotomy group and EA group had obvious changes in HSS index before and after the therapy (P < 0.01). And there was remarkable difference in HSS index variation between the groups (P < 0.01). Acupotomy group and EA group showed big difference in pain index before and after treatment (P < 0.01). Apparent difference also existed in the comparison among groups (P < 0.01). Both acupotomy group and EA group had apparent changes in infrared thermal imaging detection before and after the treatment (P < 0. 01).
CONCLUSION: Acupotomy and EA both have significant effects in KOA treatment; the former is better than the latter in relieving pain and improving knee functions.

J Tradit Chin Med. 2016 Aug;36(4):450-5.

Source: PubMed


Epigallocatechin Gallate Upregulates NRF2 to Prevent Diabetic Nephropathy via Disabling KEAP1

Sun W1, et al.

Epigallocatechin gallate (EGCG) is the most abundant and effective green tea catechin and has been reported to attenuate diabetic nephropathy (DN). However, the mechanism by which EGCG ameliorates DN, till now, has remained unclear. EGCG is known as a potent activator of nuclear factor erythroid 2-related factor 2 (NRF2), which plays a key role in cellular defense against diabetes-induced oxidative stress and in the prevention of DN. In the present study, we tested whether NRF2 is required for EGCG protection against DN. Therefore, C57BL/6 wild type (WT) and Nrf2 knockout mice were induced to diabetes by streptozotocin, in the presence or absence of a 24-week treatment with EGCG. In the WT mice, EGCG activated Nrf2 expression and function without altering the expression of Kelch-like ECH-associated protein 1 (Keap1). Diabetes-induced renal oxidative damage, inflammation, fibrosis and albuminuria were significantly prevented by EGCG. Notably, deletion of the Nrf2 gene completely abrogated these actions of EGCG. To further determine the effect of EGCG on KEAP1/NRF2 signaling, mouse mesangial cells were treated with high glucose, in the presence of both Keap1 siRNA and EGCG. Interestingly, EGCG failed to enhance NRF2 signaling and alleviate oxidative, inflammatory and fibrotic indicators, in the presence of Keap1 siRNA. The present study demonstrated, for the first time, that NRF2 plays a critical role in EGCG protection against DN. Other findings indicated that inactivation of KEAP1 protein by EGCG may mediate EGCG function in activating NRF2.

Free Radic Biol Med. 2017 Apr 27. pii: S0891-5849(17)30568-3. doi: 10.1016/j.freeradbiomed.2017.04.365. [Epub ahead of print]

Source: PubMed


Effects of Astragalus Combined with Angelica on Bone Marrow Hematopoiesis Suppression Induced by Cyclophosphamide in Mice

Li F1, et al.

Danggui Buxue Tang (DBT), a combination of Astragalus and Angelica at a 5 : 1 ratio, mainly promotes hematopoiesis. However, in the clinic, the combination ratio of Astragalus and Angelica to treat low hematopoietic function is not an absolute 5 : 1 ratio, suggesting that the herbs may promote hematopoiesis better after being combined at a certain range of ratios. The objective of this study is to investigate the effect of different ratio combinations of Astragalus and Angelica on bone marrow hematopoiesis suppression induced by cyclophosphamide (CTX) and to probe the interaction and mechanism of Astragalus combined with Angelica in promoting hematopoiesis. Following establishment of the model, mice were administered with Astragalus (6.00 gkg-1), Angelica (3.00 gkg-1), and combinations of Astragalus and Angelica at different ratios, including 10 : 1 (Astragalus 9.81 gkg-1+Angelica 0.98 gkg-1), 5 : 1 (Astragalus 9.00 gkg-1+Angelica 1.80 gkg-1), 2 : 1 (Astragalus 7.71 gkg-1+Angelica 3.08 gkg-1), 1 : 1 (Astragalus 5.40 gkg-1+Angelica 5.40 gkg-1), 1 : 2.5 (Astragalus 3.08 gkg-1+Angelica 7.71 gkg-1), 1 : 5 (Astragalus 1.80 gkg-1+Angelica 9.00 gkg-1), and 1 : 10 (Astragalus 0.98 gkg-1+Angelica 9.81 gkg-1). Our results suggested that Astragalus mixed with Angelica synergistically promoted hematopoiesis best when the combination ratio of Astragalus and Angelica was 1 : 1, 1 : 2.5 or 1 : 5; moreover, the effect of Angelica was greater than that of Astragalus. The potential mechanisms of the combinations of Astragalus and Angelica that promote hematopoiesis include the dissolution of the effective components, promoting the synthesis and secretion of hematopoietic growth factor (HGF) and the proliferation of hematopoietic progenitor cells (HPCs).

Biol Pharm Bull. 2017;40(5):598-609. doi: 10.1248/bpb.b16-00802.

Source: PubMed


Featured Products

Chinese Herbs

TCM Books

TOW Store
This Month's Articles

June 2017

Volume 15, Number 6

Points of Interest

Acupuncture Point Location Center

Clinical Doctoral Program

Today's TCM Tip

For inflammation, add LI4 and LI11

Keep Informed

Sign Up for Our
FREE e-Newsletter

All Contents Copyright 1996-2015 Cyber Legend Ltd. All rights reserved. Use of this website is subject to our Terms and Conditions. All logos, service marks and trademarks belong to their respective owners.

Legal Disclaimer Notice: The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.